Extended Data Fig. 4: SURMOUNT-3 study design. | Nature Medicine

Extended Data Fig. 4: SURMOUNT-3 study design.

From: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

Extended Data Fig. 4

This is a phase 3, multicenter, randomized, placebo-controlled, double- blinded clinical trial investigating the efficacy and safety of maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg) administered once weekly (QW) subcutaneously compared with placebo for body weight management, in participants who have obesity, or overweight with at least 1 obesity-related complication (excluding type 2 diabetes), and with at least 5% weight reduction following a 12-week intensive lifestyle intervention lead-in. All randomized participants were planned to undergo a 72-week treatment period.

Back to article page